Transportation testing performed for the trak back ii device resulted in an 11% failure rate for bubble emission.Upon review, the determination was made that the sterility of the product following the shipment process might be compromised.To date, volcano corporation has not received any reports from customers/users regarding this issue.Additionally, there are no reported cases of patient injury or adverse events that could be potentially related to this failure mode.
|
Reference #2939520-8/14/14-001r.During planned manufacturing transfer activities, a routine review of the design history record was conducted.During this review, it was discovered that the transportation validation documentation could not be located.A transportation validation was conducted.During the bubble emission portion of the test, (b)(4) packages tested failed the bubble emission test.Volcano initiated a voluntary recall of all lots of trak back ii distributed within the previous 25 months.Further information regarding this activity will be communicated to fda via routine communications relative to the above referenced recall notification number.
|